ADCI National Institutes of Health

IDrugs

Volumn 1, Issue 3, 1998, Pages 339-343

  Varming, Thomas ^a  

^a NEUROSEARCH A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748131834     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Protection against dendrotoxin-induced clonic seizures in mice by anticonvulsant drugs. Coleman MH, Yamaguchi S, Rogawski MA BRAIN RES 1992 575 138-142
2. Anticonvulsant activity of the low-affinity uncompetitive N-methyl-D-aspartate antagonist (+)-5-aminocarbonyl-10,11-dihydro- 5H-dibenzo[a,d]cyclohepten-5,10-imine (ADCI): Comparison with the structural analogs dizocilpine (MK-801) and carbamazepine. Rogawski MA, Yamaguchi S-I, Jones SM, Rice KC, Thurkauf A, Monn JA J PHARMACOL EXP THER 1991 259 1 30-37
3. Comparison of the effects of the uncompetitive N-methyl-D-aspartate antagonist (+)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten- 5,10-imine (ADCI) with its structural analogs dizocilpine (MK-801) and carbamazepine on ethanol withdrawal seizures. Grant KA, Snell LD, Rogawski MA, Thurkauf A, Tabakoff B J PHARMACOL EXP THER 1992 260 3 1017-1022
4. The anticonvulsant (+)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (ADCI) selectively blocks NMDA-activated current in cultured rat hippocampal neurones: Kinetic analysis and comparison with dizocilpine. Jones SM, Rogawski MA MOL NEUROPHARMACOL 1992 2 303-310
5. Synthesis and structure-activity relationship of C5-substituted analogues of (+)-10,11-dihydro-5H-dibenzo[a,d] cyclo-hepten-5,10-imine [(+)-desmethyl-MK801]: Ligands for the NMDA receptor-coupled phencyclidine binding site. Monn JA, Thurkauf A, Mattson MV, Jacobson AE, Rice KC J MED CHEM 1990 33 1069-1076
6. Neurogen and NIH finalize Crada and Anticonvulsant license Neurogen Corp PRESS RELEASE 1992 March 03
7. Neurogen Corp ANNUAL REPORT 1993
8. Neurogen Corp ANNUAL REPORT 1994
9. Neurogen and Wyeth-Ayerst announce licensing agreement for epilepsy drug. Neurogen Corp PRESS RELEASE 1996 November 26
10. Company news in brief. SCRIP 1996 2187 11
11. Bromine-promoted cyclization of an olefinic α-aminonitrile: A practical synthesis of 5-aminocarbonyl-10,11-dihydro-5H- dibenzo[a,d]cyclohepten-5,10-imine (ADCI). Gonzalez J, Carroll FI TETRAHEDRON LETT 1996 37 48 8655-8658
12. Neurogen sell epilepsy drug rights to AHP, revises anti-anxiety program with Pfizer. EMERGING PHARMACEUTICALS 1997 6 1 1
13. Anticonvulsant efficacy of ADCI (5-aminocarbonyl-10,11-dihydro-5H- dibenzo[a,d]cyclohepten-5,10-imine) after acute and chronic dosing in mice. Rogawski MA, Le DQ, Uyakul D, Pannell LK, Subramaniam S, Yamaguchi SI, Kokate TG EPILEPSIA 1995 36 6 566-571
14. The broad spectrum anticonvulsant ADCI blocks TTX sensitive voltage-activated Na channel currents in NE1-115 mouse neuroblastoma cells. White G SOC NEUROSCI ABSTR 1994 20 1-2 1239
15. Schering-Plough fee boosts Neurogen in 1996. SCRIP 1997 2215 8
16. Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Grant KA, Colombo G, Grant J, Rogawski MA NEUROPHARMACOLOGY 1996 35 12 1709-1719
17. Two new Neurogen drug candidates enter clinical trials. Neurogen Corp PRESS RELEASE 1997 July 31
18. Behavioural pharmacology of the non-competitive NMDA antagonists dextrorphan and ADCI: Relations between locomotor stimulation, anticataleptic potential and forebrain dopamine metabolism. Bubser M, Zadow B, Kronthaler UO, Felsheim U, Rueckert NGH, Schmidt WJ NAUNYN SCHMIEDEBERG'S ARCH PHARMACOL 1997 355 6 767-773
19. ADCI CLIN TRIALS MONITOR 1997 6 9 6
20. Neurogen announces completion of phase Ia study with ADCI for epilepsy. Neurogen Corp PRESS RELEASE 1997 October 27
21. Neurogen reports third quarter financial results. Neurogen Corp PRESS RELEASE 1997 November 06
22. Analyst Report 1997. BancAmerica Robertson Stephens ANALYST REPORT 1997
23. Trials planned. CLIN TRIALS MONITOR 1997 6 12 1
24. Channel block of NMDA receptors by the anticonvulsant ADCI: Studies with cloned NR1a-NR2A and NR1a-NR2B subunits. Harty TP, Rogawski MA SOC NEUROSCI ABSTR 1997 23 Part 2 2165
25. Evaluation of ADCI against convulsant and locomotor stimulant effects of cocaine: Comparison with the structural analogs dizocilpine and carbamazepine. Seidleck BK, Thurkauf A, Witkin JM PHARMACOLOGY 1994 47 4 839 - 844
26. Pharmacokinetics of positive ADCI tartrate in rat plasma and brain following single and multiple oral administration. Changchit A, Jou JC, Gallager D, Shaw K PHARM RES 1994 11 (10 Suppl) 343
27. Toxicokinetics of (positive) ADCI tartrate during thirty-day oral dose range finding toxicity study in rats. Changchit A, Jou JC, Gallager D, Shaw K PHARM RES 1994 11 (10 Suppl) S343
28. Tolerance to the anticonvulsant activity of the low-affinity, uncompetitive NMDA antagonist ADCI is due to induction of metabolism. Rogawski MA, Yamaguchi S, Uyakul D, Pannell LK, Subramanian S, Kokate TG, Le DQ EPILEPSIA 1993 34 SUPPL. 6 86
29. ADCI, a novel anticonvulsant, does not impair avoidance or spatial learning in the rat. Rajachandran L, Kastello AD, Cassella JV, Thurkauf A, Marshall L, Hutchison AJ, Tallman J F SOC NEUROSCI ABSTR 1993 19 1-3 1630